Patents Assigned to Medical Sciences Research Institute
-
Patent number: 5817312Abstract: The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e.g., wounds, burns, etc.), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.Type: GrantFiled: October 14, 1997Date of Patent: October 6, 1998Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Girish Giridhar
-
Patent number: 5770234Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable particle to prime macrophages for enhanced oxidative response and bacterial killing. The phagocytosable particles should be administered at the time of exposure to contagion, or one day prior to or up to 6-12 hours after exposure. Administration can be performed by any suitable means which will bring the particles quickly into contact with the blood stream where they will encounter phagocytes and cause priming of the patient's macrophages. The augmentation technique provides for non-specific cellular immunity from a wide range of contagion.Type: GrantFiled: December 13, 1996Date of Patent: June 23, 1998Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Girish Giridhar
-
Patent number: 5681565Abstract: The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e.g., wounds, burns, etc.), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.Type: GrantFiled: January 24, 1996Date of Patent: October 28, 1997Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Girish Giridhar
-
Patent number: 5591441Abstract: A non-specific host immune cell augmentation composition for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.Type: GrantFiled: February 16, 1994Date of Patent: January 7, 1997Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Quentin N. Myrvik
-
Patent number: 5585106Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable particle to prime macrophages for enhanced oxidative response and bacterial killing. The phagocytosable particles should be administered at the time of exposure to contagion, or one day prior to or up to 6-12 hours after exposure. Administration can be performed by any suitable means which will bring the particles quickly into contact with the blood stream where they will encounter phagocytes and cause priming of the patient's macrophages. The augmentation technique provides for non-specific cellular immunity from a wide range of contagion.Type: GrantFiled: June 7, 1995Date of Patent: December 17, 1996Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Girish Giridhar
-
Patent number: 5505945Abstract: Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, Coagulase Negative Staphylococci Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release.Type: GrantFiled: August 25, 1994Date of Patent: April 9, 1996Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Quentin N. Myrvik